RxDoctor Payments Data

Gurmit Gill, MD

Pulmonary Disease · Garden City, NYNPI 1730134339

Payments from drug & device makers

$140,449in general payments, 2019–2025

Across 1,714 payments — averaging $81.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$45K
  • Mallinckrodt Enterprises LLC$32K
  • Mylan Specialty L.p.$12K
  • Sunovion Pharmaceuticals Inc.$8K
  • Novartis$8K
  • AstraZeneca$5K
  • plus $30K from 54 others

What the payments were for

  • Consulting fees$3,5353%
  • Speaking & faculty fees$85,45864%
  • Travel & lodging$2,4182%
  • Food & beverage$40,79531%
  • Education$9361%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mallinckrodt Hospital Products Inc.79$44,704
Mallinckrodt Enterprises LLC35$32,442
Mylan Specialty L.p.55$12,416
Sunovion Pharmaceuticals Inc.43$8,065
Novartis18$7,721
AstraZeneca182$5,120
GSK198$4,208
Harmony Biosciences LLC192$3,946
Regeneron Healthcare Solutions, Inc.97$3,018
Jazz Pharmaceuticals Inc.68$2,000
Sanofi52$1,538
Boehringer Ingelheim58$1,457
Grifols USA, LLC54$1,436
Genentech USA, Inc.56$1,107
Amgen(2 entities)53$1,050
Takeda Pharmaceuticals U.S.A., Inc.37$868
Philips North America LLC51$855
ANI Pharmaceuticals, Inc.26$617
Optinose US, Inc.30$600
Electromed, Inc.31$553
Merck22$478
Arbor Pharmaceuticals, Inc.31$472
Insmed, Inc.14$463
Baxter Healthcare14$427
Axsome Therapeutics, Inc.17$407
Alk-abello, Inc25$402
Shire North American Group Inc12$329
Advanced Respiratory, Inc14$312
Pfizer10$237
Teva Pharmaceuticals USA, Inc.10$220
Verona Pharma, Inc.7$215
Paratek Pharmaceuticals, Inc.9$214
Idorsia Pharmaceuticals US Inc13$199
Eisai Inc.10$188
Novo Nordisk8$187
Vertex7$186
Gilead10$172
Nabriva Therapeutics, PLC7$148
Hikma Pharmaceuticals USA7$146
Resmed Corp3$143
Viatris Specialty LLC5$118
AbbVie5$114
Sanofi-aventis U.S. LLC1$97
CSL Behring4$92
ARS Pharmaceuticals Operations, Inc.3$87
Actelion Pharmaceuticals US, Inc.4$84
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$84
Lilly USA, LLC3$73
Pharming Healthcare, Inc.3$69
Circassia Inc.4$69
Johnson & Johnson2$42
Inogen, Inc.2$33
Currax Pharmaceuticals LLC2$29
3b Medical, Inc.2$29
Lundbeck LLC1$27
Intra-sana Laboratories1$24
LEO Pharma Inc.1$24
Inspire Medical Systems, Inc.1$20
Supernus Pharmaceuticals, Inc.1$19
Eyevance Pharmaceuticals LLC1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$140,449 in reported general payments places this provider in the 90th percentile of 1,115 pulmonary disease providers in New York.

See all pulmonary disease providers in New York

Medicare billing

Part B allowed, 2024
$383,342
Medicare patients
256
Services billed
11,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab270$1,004,714
XembifyImmune Globulin,gamma(Igg)klhw13$163,346
GlassiaAlpha-1-Proteinase Inhibitor11$140,376
Trelegy ElliptaFluticasone/Umeclidin/Vilanter152$103,529
XolairOmalizumab28$100,168
Dupixent PenDupilumab23$85,098
TezspireTezepelumab-Ekko18$75,533
WakixPitolisant Hcl11$64,304
OzempicSemaglutide45$52,807
NuzyraOmadacycline Tosylate11$50,280
MounjaroTirzepatide46$46,788
Breztri AerosphereBudesonide/Glycopyr/Formoterol53$38,638
Zileuton ErZileuton18$31,008
Spiriva RespimatTiotropium Bromide27$23,363
RybelsusSemaglutide19$18,358

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCXembify$1,436$163,34613 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$868$140,37611 claims
AstraZenecaTezspire, Breztri Aerosphere$5,120$114,17171 claims
GSKTrelegy Ellipta$4,208$103,529152 claims
Novo NordiskOzempic, Rybelsus$187$71,16664 claims
Harmony Biosciences LLCWakix$3,946$64,30411 claims
Paratek Pharmaceuticals, Inc.Nuzyra$214$50,28011 claims
Lilly USA, LLCMounjaro$73$46,78846 claims
Boehringer IngelheimSpiriva Respimat$1,457$23,36327 claims
AbbVieLinzess$114$5,49911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,115 pulmonary disease providers in New York.

Other pulmonary disease in Garden City

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →